T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

trastuzumab plus an additional HER2-directed ... Supported by F. Hoffmann–La Roche/Genentech. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Roche Holding AG's acquisition of Poseida for ... breast cancer therapies Perjeta and Herceptin, solid tumor cancer immunotherapy Tecentriq, and immunology drug Actemra, which drove nearly $ ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).